Dr. Ahmed Farhan
If you have PCOS, or think you might, you may have noticed something strange this year: your condition has a new name.
Doctors, researchers, and patient groups around the world just agreed to stop calling it polycystic ovary syndrome (PCOS). The new name is polyendocrine metabolic ovarian syndrome, or PMOS.
That is a mouthful. But the reason behind the change is simple, and it matters a lot if you are trying to manage your weight or your blood sugar.
The old name made PCOS sound like a problem with cysts on your ovaries. The new name says something very different: this is a whole-body condition, and insulin, the hormone that controls your blood sugar, sits right at the center of it.
Here is what actually changed, what the science behind it says, and what it means for how PCOS, now PMOS, gets diagnosed and treated.
Why this is suddenly everywhere
In May 2026, a paper in the medical journal The Lancet announced the results of an 11-year effort to rename PCOS.
The project asked more than 22,000 people with the condition, along with doctors and researchers, what the name should be.
More than 50 patient and professional groups took part, including the Endocrine Society and the American Society for Reproductive Medicine.
The result: polycystic ovary syndrome is now called polyendocrine metabolic ovarian syndrome, or PMOS.
Health systems, journals, and patient groups are in the middle of a three-year transition, so you will likely see both names used for a while. Some doctors will still say PCOS. Some will say PMOS. Right now, they mean the same condition.
What the research behind the name change actually found
This was not a marketing decision. It came out of a formal, years-long research process. Surveys of patients and health professionals found that 86 percent of patients and 71 percent of doctors supported moving to a name that better reflected the condition’s biology, rather than keeping an acronym built around one visual finding on an ultrasound.
The core problem with the old name: ‘polycystic ovary’ focuses on one thing, the appearance of the ovaries on an ultrasound.
But researchers have known for years that the ovaries are only part of the picture. The condition also involves your hormones more broadly, your metabolism, your skin, and even your mental health.
Naming it after the ovaries alone led to missed diagnoses, because people (and sometimes doctors) assumed ‘no visible cysts’ meant ‘no PCOS.’ It also meant the weight and blood sugar side of the condition often got less attention than the reproductive side.
The new name spells out three parts on purpose. ‘Polyendocrine’ means several hormone systems are involved, not just the ovaries.
‘Metabolic’ names the connection to blood sugar, insulin, and weight directly, instead of leaving it as an unspoken side effect. ‘Ovarian’ keeps the reproductive piece, because it is still real and still matters.
The real story: insulin, not just ovaries
Here is the part that matters most for a metabolic health audience. A large and growing body of research shows that insulin resistance is not a side effect of PCOS. It is one of the engines driving it.
Insulin resistance means your cells stop responding well to insulin, the hormone that moves sugar out of your blood and into your cells for energy.
When your cells resist insulin’s signal, your pancreas pumps out more of it to compensate. That extra insulin does not just sit quietly in the background.
It pushes your ovaries to make more testosterone and other male-pattern hormones, which can worsen acne, hair growth, and irregular periods.
It also promotes fat storage, especially around the belly, which can make insulin resistance worse. This becomes a loop that feeds itself.
Estimates vary depending on how it is measured. Still, medical references now cite that somewhere between one third and two thirds of people with PMOS have a meaningful degree of insulin resistance.
The number is higher in people who also have excess weight. A 2026 review in the Journal of Internal Medicine describes insulin resistance and the extra insulin it causes as a central mechanism connecting the reproductive, skin, and metabolic sides of the condition, not three separate problems happening at once.
This is why researchers pushed for the word ‘metabolic’ to be in the name. If insulin is part of what is driving your periods, your skin, and your weight, then treating PCOS/PMOS only as a fertility issue was always missing a large piece of the picture.
What actually changes in diagnosis and care
The diagnosis itself has not changed. Doctors still look for two out of three features: signs of extra male-pattern hormones (like acne or extra hair growth), irregular or absent ovulation, and a polycystic-appearing ovary on ultrasound. What is shifting is what happens after diagnosis.
Some researchers are now recommending a move away from screening mainly with a fasting glucose test and toward more insulin-focused testing at diagnosis, such as a glucose tolerance test that also checks how your insulin responds, not just your sugar level.
The idea is that insulin problems can show up years before blood sugar itself becomes abnormal. Catching that earlier gives you and your doctor a longer runway to act on weight, activity, and other risk factors before prediabetes or type 2 diabetes develops.
Current clinical guidance also calls for checking blood pressure, cholesterol, and body measurements like BMI and waist size at the time of diagnosis, along with screening for mood and anxiety symptoms and, for some, obstructive sleep apnea.
None of this is new to good PCOS care, but naming ‘metabolic’ directly in the condition’s title is meant to make this kind of full-body screening the default, not an extra step some doctors remember to do and others skip.
What we know
We know the name change reflects real, established science, not a rebrand for its own sake. The link between insulin resistance and PCOS/PMOS is one of the most studied relationships in reproductive endocrinology, going back decades.
We know insulin resistance is common in PMOS, though not universal, and that it tends to be worse in people carrying more weight, especially around the abdomen.
We know the three core diagnostic features have not changed, so nobody needs to be rediagnosed because of the new name alone.
What we don’t know yet
Researchers still do not fully agree on the best single test for insulin resistance in everyday clinical practice, which is part of why testing approaches vary between doctors and countries.
It is also not yet settled exactly how quickly, or how completely, health systems, insurers, and medical records will adopt the new PMOS name, since that kind of large-scale change takes years to filter through paperwork and billing codes.
And while several small studies have looked at newer weight-loss medications for PCOS/PMOS, larger and longer trials are still needed before anyone can say how they compare to established options over years, not months.
Common misconceptions about PCOS and PMOS
“It’s just about having cysts on your ovaries.” Many people with the condition never have cysts show up on an ultrasound at all, and having ovarian cysts alone does not mean you have PCOS/PMOS. The ovarian finding is just one of three features doctors look for, and you only need two of the three.
“If I’m not overweight, insulin resistance doesn’t apply to me.” Insulin resistance shows up in people with PMOS across a range of body sizes, not only in people who are overweight or obese. Body weight changes the odds; it does not decide them on its own.
“The new name means it’s a completely different, more serious condition.” It is the same condition, with the same diagnostic criteria. The name is catching up to decades of research, not describing something new that just appeared.
Who should pay closer attention?
If you already have a PCOS or PMOS diagnosis, this is a good moment to ask your doctor whether your metabolic screening is up to date: blood pressure, cholesterol, blood sugar or insulin testing, and weight and waist measurements.
If you have irregular periods, acne that has not responded to typical treatment, unexplained extra hair growth, or a family history of the condition, and you have not been evaluated, this is also a reasonable moment to bring it up, since underdiagnosis has been a persistent problem, especially in people who are not visibly overweight.
Teenagers and young adults are a particular focus too, since symptoms often start in the teen years but can be dismissed as normal puberty.
Practical, evidence-based steps
None of this is a substitute for a conversation with your own doctor, but here is what the evidence broadly supports as useful ground to cover:
- Ask whether your last metabolic screening (blood pressure, cholesterol, blood sugar or insulin, weight, and waist size) is current, since guidelines call for this at diagnosis and periodically afterward.
- If you have not had your insulin response evaluated and you have symptoms like irregular periods, acne, or excess hair growth, ask whether it is worth discussing, especially if fasting glucose alone has come back normal.
- Regular movement and strength-building activity are consistently linked to better insulin sensitivity in research on PCOS/PMOS, independent of whether they lead to weight loss.
- Getting consistent, adequate sleep is tied to better hormone and blood sugar regulation in the broader research on metabolic health, and disrupted sleep is common in PCOS/PMOS.
- If weight-loss medications come up in conversation with your doctor, know that researchers are actively studying the GLP-1 drug class (the same family used for type 2 diabetes and general weight management) in PCOS/PMOS specifically, with encouraging but still early results. This is a conversation to have with your prescriber, not a do-it-yourself decision.
Frequently asked questions
Is PMOS a different condition than PCOS?
No. It is the same condition with a new, more accurate name. Anyone diagnosed with PCOS already meets the definition of PMOS.
Do I need to get rediagnosed?
No. The diagnostic criteria have not changed. If you were diagnosed with PCOS, that diagnosis carries over under the new name.
Why does insulin matter so much in PMOS?
Because extra insulin in your bloodstream pushes your ovaries to produce more male-pattern hormones and encourages fat storage, which can worsen both the reproductive and metabolic symptoms of the condition. It is one of the central mechanisms connecting the different parts of PMOS.
Does the new name change my treatment?
Not automatically, but it is meant to push doctors toward treating the metabolic side, like blood sugar, weight, and cardiovascular risk, with the same attention as the reproductive side, rather than treating it as an afterthought.
Is PMOS only about weight?
No. It affects your hormones, your skin, your reproductive system, and your mental health too. Weight and insulin are a major part of the picture, but not the whole picture.
Will my doctor use the new name right away?
Maybe not. The transition is expected to take about three years across health systems, medical records, and insurance coding, so you will likely hear both PCOS and PMOS used interchangeably for some time.
The bottom line
A name change can sound like a small thing. This one is not. It is the medical field formally acknowledging what the research has shown for years: PCOS, now PMOS, is a metabolic condition as much as a reproductive one, and insulin resistance is one of its central drivers.
If you have this condition, the most useful takeaway is not the new letters. It is the reminder to make sure your care is treating the whole picture, blood sugar and metabolic health included, not just the parts that show up on an ultrasound.
References
Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published online May 12, 2026. [Ref]
Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. Press release, May 2026.
American Society for Reproductive Medicine (ASRM). PCOS is Now PMOS: Understanding the Name Change. May 27, 2026.
AJMC. PCOS Renamed PMOS in Landmark Shift Reflecting Metabolic and Endocrine Features.
Merck Manual, Professional Edition. Polyendocrine Metabolic Ovarian Syndrome (PMOS) — Gynecology and Obstetrics. Reviewed June 2026.
StatPearls (NCBI Bookshelf). Polyendocrine Metabolic Ovarian Syndrome.
Forslund M, et al. Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk. Journal of Internal Medicine, 2026.
Journal of Clinical Investigation (JCI). Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): current and future trends.
Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. Journal of Ovarian Research, 2015.
Obesity, Insulin Resistance, and Infertility in Women with Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study at a Tertiary Referral Medical Center in Qatar. PMC, 2026.
